UK scientists melt 'world's oldest ice' to reveal Earth's ancient history
What's the latest?
For the next seven weeks, a team based in the UK city of Cambridge will slowly melt the Antarctic ice.But it's not the ice itself the scientists are interested in, it's what's trapped within it.This will release ancient dust, volcanic ash, and even tiny marine algae that were locked inside when water turned to ice.These materials can help scientists better understand what wind patterns, temperature, and sea levels were like more than a million years ago.Scientists are excited about what the melted ice could reveal.Dr Liz Thomas, head of ice core research at the British Antarctic Survey explained: "This is a completely unknown period of our Earth's history"Our climate system has been through so many different changes that we really need to be able to go back in time to understand these different processes and different tipping points," Dr Thomas added.This air and other particles formed hundreds of thousands of years ago, which scientists hope could provide us with important information about the Earth's past.It's thought it could also help solved one of the major mysteries in our planet's climate history.
How was the ice extracted?
The ice was extracted by an international team of scientists, which was led by the Italian Institute of Polar Sciences and included 10 European nations.Working at temperatures of -35C, the team drilled a 1.7 mile-long piece of ice from deep within Antarctica.That's the same length as just over 26-and-a-half professional football pitches!The ice was chopped into one metre blocks and was carefully transported by boat from Antarctica and then by road to various scientific laboratories in Europe - including the UK, Germany and Switzerland.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
2 minutes ago
- Telegraph
Antibodies raise vaccine hopes for a bug that kills 500,000 a year
The discovery of antibodies thought to protect children against a common bacterial infection could bring a vaccine against a bug that kills 500,000 each year. Scientists at the University of Sheffield and the Medical Research Council (MRC) have for the first time identified specific antibodies that protect against Strep A. The common bacterium is mainly known for causing sore throats and flu-like symptoms, but in more invasive cases it can be deadly. The bug kills hundreds of thousands of people each year in poor and middle-income countries, and a UK outbreak in 2022/23 caused more than 400 deaths. Researchers tracked children in The Gambia, and discovered that while maternal protection faded, young children quickly mounted immune responses to parts of the bug. Until now, a limited understanding of the body's natural defences against the bug, which is also called Streptococcus pyogenes, has hindered any vaccine development. The findings of the peer-reviewed study, which are published in the Nature Medicine journal, are a potential breakthrough to develop a new jab. Dr Alex Keeley, a Wellcome fellow in global health at the MRC's Gambia unit and Sheffield's Florey Institute of Infection, led the research. He said: 'Our findings represent a significant step towards a safe and effective vaccine that could save around half a million lives here in the UK and around the world.' 'Now, for the first time in humans, we've been able to observe how antibodies that would be made following vaccination may be preventing infections and show how these antibodies may be working against Strep A.' Fatouamta Camara, who worked on the research, said Strep A in the Gambia 'carries a devastating burden on children and adults in their prime years'. She said: 'Beyond causing illness, its impact ripples through families and communities, perpetuating cycles of poverty and reducing quality of life. 'A vaccine offers hope as a powerful tool to prevent these infections, protect our communities, and improve health outcomes, enabling children and young people to thrive.'
Times
30 minutes ago
- Times
Who will be the next Bond girl? From Marisa Abela to Zendaya
S lowly but surely, the pieces of the next Bond film are falling into place. We know that Denis Villeneuve (best known for the Dune films) will direct the first instalment in Amazon MGM Studios' relaunch of the famous spy franchise. We also know that Peaky Blinders creator Steven Knight is the one picking up his pen to write the script. But what we're yet to find out is which two actors will eventually strike steely-eyed poses on the poster. Who will replace Daniel Craig as 007? And which star will follow Ana de Armas in becoming a Bond girl? While we await confirmation of this all-important casting, here are our top guesses of who might play the secret agent's sexy sidekick … 28, British Best known for playing Amy Winehouse in Back to Black and Yasmin in the finance drama Industry, Abela is no stranger to onscreen espionage. This year she appeared in Steven Soderbergh's thriller Black Bag as a satellite imagery specialist working for the National Cyber Security Centre. Early in the film, she stabs her cheating boyfriend through the hand with a steak knife. Pretty hardcore.
Telegraph
an hour ago
- Telegraph
Prostate cancer breakthrough cuts risk of erectile dysfunction
Men having prostate cancer treatment could be spared erectile dysfunction thanks to a breakthrough. The ERECT trial, investigating methods to preserve erectile function in men undergoing treatment, treated them using MRI-guided radiotherapy. This method targets the prostate while avoiding the nerves and blood vessels needed for erections. Erectile dysfunction is one of the most common side-effects of prostate cancer treatment, especially following radiotherapy or surgery. Treatments can affect the nerves and blood vessels involved in achieving and maintaining an erection, leading to varying degrees of sexual dysfunction in many patients. The study, by University Medical Centre Utrecht, found the targeted method had less than half the risk of erectile dysfunction compared with standard techniques. In the UK, prostate cancer is the most common cancer in men. Each year, approximately 55,000 men are diagnosed with it and, despite advances in detection and treatment, around 12,000 die from the disease annually with around 10,000 deaths a year in England. The incidence of prostate cancer has been rising, partly because of increased awareness and PSA testing. However, survival rates have also improved significantly. Nearly 80 per cent of men diagnosed with prostate cancer today are expected to survive for at least 10 years. The Telegraph is campaigning for the introduction of targeted screening for prostate cancer. Health advisers are currently considering the evidence for rolling out screening that could target tests to those at increased risk of the disease, such as black men or those with a family history of the disease. However, getting the focus right is crucial. Too many false positives can lead to over treatment of slow-growing disease, which can mean needless potentially distressing side-effects. Dr Jochem van der Voort van Zyp, the lead investigator, said: 'With MRI guidance, we limit radiation to erectile tissues but still treat the prostate effectively. With the enhanced precision of MRI guidance, we gain the confidence to limit the dose these erectile tissues receive. 'The prostate gets the therapeutic dose while the erectile tissues receive a much lower dose, thus preserving their function.' The trial of 70 men found that, at six months, six per cent had erectile dysfunction, compared to 21 per cent with conventional treatment. After 18 months, 16 per cent experienced dysfunction compared to 36 per cent in the control group. Experts said the new technique could offer men a better chance of maintaining sexual function following prostate cancer treatment without compromising cancer control. It is estimated that more than 16,000 men a year – those with low to intermediate risk disease – who receive radiotherapy could potentially benefit from such advances. So far, the technology is being used at the The Royal Marsden NHS Foundation Trust and The Christie NHS Foundation Trust in Manchester, with plans for rollout to two more sites. The device used, the Elekta Unity MR-Linac, combines MRI with radiation delivery for precise treatment. It allows doctors to see the prostate and surrounding tissues in detail and adjust treatment in real-time to avoid damaging healthy structures. John Christodouleas, Elekta's senior vice president of medical affairs, said: 'These results add to growing evidence that minimising radiation to normal tissues improves quality of life for men with prostate cancer.' Elekta Unity MR-Linac is the world's first and only device to combine a high-field MRI with a state-of-the-art linear accelerator. Experts said that enabled clinicians to use imaging to guide radiation delivery to tumour targets and avoid surrounding structures. In addition, while treatment is ongoing, the system allows clinicians to non-invasively monitor the position of the target. If, for example, if the prostate shifts because of motion of the bowels or bladder filling, the radiation treatment can be discontinued to avoid unnecessary radiation to surrounding normal tissues. The preliminary results were presented by clinicians from University Medical Centre Utrecht at the European Society for Radiotherapy and Oncology annual congress earlier this year.
